COVID-19 infection is associated with increased initiation of pharmacotherapy for autonomic dysfunction, with sustained risk observed beyond one year.
Does COVID-19 infection increase the initiation of pharmacotherapy for autonomic dysfunction in a nationwide Japanese cohort?
COVID-19 infection is associated with a sustained, long-term increased risk of requiring pharmacotherapy for autonomic dysfunction.
Absolute Event Rate: 0% vs 0%
COVID-19 infection is significantly associated with increased initiation of pharmacotherapy for autonomic dysfunction, with sustained risk beyond one year. These findings highlight the to manage autonomic dysfunction among COVID-19 survivors and informing clinical care and public health planning.
Miyamori et al. (Tue,) reported a other. COVID-19 infection is associated with increased initiation of pharmacotherapy for autonomic dysfunction, with sustained risk observed beyond one year.